尿液来源DNA检测微小残留病灶可预测卡介苗无反应性非肌层浸润性膀胱癌接受Nadofaragene Firadenovec治疗后的无复发生存
本研究在平行臂2期试验(NCT01687244)中,对卡介苗无反应性高级别非肌层浸润性膀胱癌患者接受Nadofaragene Firadenovec治疗前(n=32)及3个月评估时(n=18)收集尿液,用UroAmp MRD检测尿液肿瘤DNA。验证版算法治疗前MRD阳性与阴性患者12个月无复发生存率分别为22%与56%(p=0.097),实验增强版算法为20%与71%(p=0.012);3个月尿液两算法均为阳性38%与阴性100%(p=0.038)。
要点
- 治疗前尿液MRD检测用实验增强版算法可区分复发风险(12个月RFS 71% vs 20%,p=0.012)。
- 3个月尿液MRD检测两算法均显示阳性患者RFS 38% vs 阴性100%(p=0.038)。
- 最常见突变为TP53、TERT、PIK3CA、ARID1A、PLEKHS1、ELF3和ERBB2。
核心结论
- Nadofaragene Firadenovec诱导治疗后尿液MRD检测对2期试验参与者的复发具有统计学显著的预后预测价值。
研究设计与样本
- 平行臂2期研究(NCT01687244)中,于诱导治疗前(n=32)和3个月评估时(n=18)收集尿液,使用UroAmp MRD检测尿液肿瘤DNA,用两种算法评估高级别NMIBC复发风险,Kaplan-Meier分析无复发生存。
主要发现
- 最常见突变为TP53、TERT、PIK3CA、ARID1A、PLEKHS1、ELF3和ERBB2。
- 治疗前尿液验证版MRD算法:阴性患者12个月RFS 56% vs 阳性患者22%(p=0.097)。
- 治疗前尿液实验增强版算法:阴性患者12个月RFS 71% vs 阳性患者20%(p=0.012)。
- 3个月尿液两算法:阴性患者RFS 100% vs 阳性患者38%(p=0.038)。
- 纵向utDNA检测将患者分类为阴性(7%)、完全缓解(13%)、部分缓解(27%)、无反应(20%)和扩展(33%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Urinary tumor DNA (utDNA) profiling identifies mutations associated with urothelial carcinoma and can be used to detect minimal residual disease (MRD). We evaluate the utility of utDNA profiling to predict treatment failure in bacillus Calmette-Guérin-unresponsive high-grade (HG) non-muscle-invasive bladder cancer (NMIBC) treated with nadofaragene firadenovec. METHODS: Urine was collected from participants prior to induction (n = 32) and at their 3-mo evaluation (n = 18) in the parallel-arm, phase 2 study (NCT01687244) of nadofaragene firadenovec. The UroAmp MRD assay (Convergent Genomics, South San Francisco, CA, USA) was used to perform utDNA testing. Risk of HG NMIBC recurrence was determined using two algorithm versions, and recurrence-free survival (RFS) was assessed using a Kaplan-Meier analysis. KEY FINDINGS AND LIMITATIONS: TP53, TERT, PIK3CA, ARID1A, PLEKHS1, ELF3, and ERBB2 were the most prevalently mutated genes. With pretreatment urine, the validated MRD algorithm resulted in 12-mo RFS of 56% for negative and 22% for positive patients (p = 0.097). The experimental, enhanced algorithm classified two additional patients as positive, giving RFS of 71% for negative and 20% for positive patients (p = 0.012). With 3-mo urine, both algorithms gave RFS of 100% for negative and 38% for positive patients (p = 0.038). Longitudinal utDNA testing classified patients as negative (7%), complete responders (13%), partial responders (27%), unresponsive (20%), and expanding (33%). CONCLUSIONS AND CLINICAL IMPLICATIONS: Urinary MRD testing after nadofaragene firadenovec induction provided statistically significant prognostication of recurrence among phase 2 trial participants. PATIENT SUMMARY: By analyzing urine-borne tumor DNA, we can help determine which patients with high-grade non-muscle-invasive bladder cancer are at the greatest risk of recurrence when receiving second-line therapy.
引用
- Narayan VM, Tholomier C, Mokkapati S, et al. Minimal Residual Disease Detection with Urine-derived DNA Is Prognostic for Recurrence-free Survival in Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer Treated with Nadofaragene Firadenovec. Eur Urol Oncol. 2024. PMID: 39406613. doi:10.1016/j.euo.2024.09.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。